25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies

Severe Symptomatic Anemia: Pathophysiology & Clinical Assessment

Severe anemia presents across a clinical spectrum defined by the acuity of onset, the efficacy of cardiovascular and biochemical compensatory mechanisms, and the presence of underlying cardiopulmonary reserve. Understanding the physiological distinction between acute hemorrhagic blood loss and chronic compensatory anemia is essential for emergency stabilization and transfusion decision-making.

Acute Blood Loss vs. Chronic Compensatory Anemia

• Acute Hemorrhagic Blood Loss:
  • Pathophysiology: The primary threat in acute hemorrhage is not the immediate loss of red blood cell mass, but the precipitous collapse of effective circulating intravascular volume leading to hypovolemic shock, diminished venous return (preload), reduced cardiac output, and inadequate tissue perfusion.
  • Diagnostic Pitfall: Initial hemoglobin and hematocrit values measured immediately following acute hemorrhage are deceptively normal. Because whole blood (plasma and erythrocytes in equal proportion) is lost simultaneously, the concentration of erythrocytes per unit volume of blood remains unchanged. A drop in hemoglobin and hematocrit only becomes evident 8 to 24 hours later, as transcapillary interstitial fluid shifts into the intravascular space and exogenous crystalloid resuscitation dilutes the remaining red blood cell mass.
  • Primary Clinical Focus: Rapid volume resuscitation with balanced crystalloids (e.g., lactated Ringer's) or immediate blood product activation (e.g., massive transfusion protocol using a 1:1:1 ratio of packed red blood cells, fresh frozen plasma, and platelets) to restore end-organ perfusion.
• Chronic Compensatory Anemia:
  • Pathophysiology: When red cell mass declines gradually over weeks to months (e.g., chronic gastrointestinal bleeding, menorrhagia, nutritional deficiencies, chronic kidney disease), the body engages robust compensatory mechanisms to preserve tissue oxygenation despite profound reductions in hemoglobin (often down to 4.0-5.0 g/dL).
  • Cardiovascular Compensation: Sustained plasma volume expansion maintains total circulating volume. Cardiac output increases through increases in resting stroke volume and resting heart rate, coupled with reduced blood viscosity (which decreases systemic vascular resistance and left ventricular afterload).
  • Biochemical Compensation (Oxyhemoglobin Dissociation Curve): Intraerythrocytic accumulation of 2,3-diphosphoglycerate (2,3-DPG) shifts the oxyhemoglobin dissociation curve to the right. This rightward shift decreases hemoglobin's affinity for oxygen, facilitating the offloading of oxygen from hemoglobin to peripheral tissues at higher capillary oxygen partial pressures.
  • Clinical Consequence: Patients with chronic severe anemia can walk into the clinic with hemoglobin levels of 4.5 g/dL reporting only mild exertional fatigue, whereas an acute drop of hemoglobin to 7.0 g/dL in a trauma patient produces diaphoresis, hypotension, and circulatory collapse.

Clinical Indicators of Hemodynamic Decompensation

Regardless of baseline chronicity, severe anemia can overwhelm compensatory capacity, resulting in critical tissue hypoxia and end-organ failure. The emergence of the following signs dictates urgent emergency department transfer and packed red blood cell (PRBC) transfusion:

1. Hemodynamic Instability: Resting tachycardia (>110 bpm), orthostatic vital sign changes (a systolic blood pressure drop ≥20 mmHg or pulse increase ≥20 bpm upon standing), or persistent resting hypotension (systolic BP <90 mmHg or mean arterial pressure <65 mmHg).
2. Myocardial Ischemia & Angina: Anemic patients with underlying coronary artery disease develop demand-supply mismatch (Type 2 Myocardial Infarction), presenting with angina pectoris, ischemic ST-segment depressions, T-wave inversions, or elevated cardiac troponins.
3. Cerebral Hypoperfusion: Lightheadedness, pre-syncope, syncope, confusion, lethargy, or altered mental status.
4. High-Output Heart Failure: Progressive exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea, bibasilar pulmonary rales, jugular venous distension, S3 gallop, and peripheral pitting edema due to excessive cardiac workload attempting to meet peripheral oxygen demands.

---

Evidence-Based Transfusion Thresholds: Restrictive vs. Liberal Strategies

For decades, clinical dogma maintained that a hemoglobin level of 10.0 g/dL (or hematocrit of 30%) was the universal minimum safe threshold (the classic '10/30 rule'). Over the past two decades, rigorous multi-center randomized controlled trials have dismantled this concept, proving that liberal transfusion strategies increase complications without conferring clinical benefit.

                  TRANSFUSION THRESHOLD PARADIGM

  ┌─────────────────────────────────────────────────────────────┐
  │ RESTRICTIVE STRATEGY (Hb < 7.0 g/dL)                        │
  ├─────────────────────────────────────────────────────────────┤
  │ • Hemodynamically stable hospitalized medical/ICU patients   │
  │ • Non-cardiac surgery patients                              │
  │ • Acute upper gastrointestinal bleeding (Villanueva trial)   │
  │ • Target Post-Transfusion Hb: 7.0 - 8.0 g/dL                 │
  │ • PROVEN BENEFITS: Reduced mortality, fewer infections,     │
  │   decreased pulmonary edema, lowered transfusion reactions   │
  └─────────────────────────────────────────────────────────────┘
                                vs
  ┌─────────────────────────────────────────────────────────────┐
  │ LIBERAL STRATEGY (Hb < 8.0 g/dL)                            │
  ├─────────────────────────────────────────────────────────────┤
  │ • Acute Coronary Syndromes (ACS) / Active Cardiac Ischemia  │
  │ • Pre-existing symptomatic cardiovascular disease undergoing │
  │   major orthopedic/vascular surgery (FOCUS trial threshold) │
  │ • Target Post-Transfusion Hb: 8.0 - 10.0 g/dL               │
  │ • Active, uncontrolled, life-threatening hemorrhage          │
  └─────────────────────────────────────────────────────────────┘

Landmark Clinical Trials Supporting Restrictive Transfusion

1. TRICC Trial (Transfusion Requirements in Critical Care, NEJM 1999):
   • Enrolled 838 critically ill, euvolemic ICU patients randomized to a restrictive strategy (transfuse if Hb <7.0 g/dL, target 7.0-8.0 g/dL) versus a liberal strategy (transfuse if Hb <10.0 g/dL, target 10.0-12.0 g/dL).
   • Key Findings: 30-day mortality was lower in the restrictive group among patients who were less critically ill (APACHE II score ≤20) and younger (<55 years). Restrictive transfusion dramatically reduced exposure to allogeneic blood products without compromising organ recovery.
2. FOCUS Trial (Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair, NEJM 2011):
   • Evaluated 2,016 elderly patients with high cardiovascular risk undergoing hip fracture surgery randomized to restrictive (transfuse for symptoms of anemia or Hb <8.0 g/dL) versus liberal (transfuse for Hb <10.0 g/dL).
   • Key Findings: No difference in mortality, functional recovery, or ambulatory ability at 60 days. A restrictive threshold of 8.0 g/dL is safe and effective in surgical patients with pre-existing cardiovascular disease.
3. Villanueva Trial (Transfusion Strategies for Upper Gastrointestinal Bleeding, NEJM 2013):
   • Evaluated 921 patients with severe acute upper gastrointestinal bleeding randomized to restrictive (transfusion threshold Hb <7.0 g/dL, target 7.0-9.0 g/dL) versus liberal (threshold Hb <9.0 g/dL, target 9.0-11.0 g/dL).
   • Critical Board Result: Mortality at 45 days was significantly lower in the restrictive group (5% vs. 9%, p=0.02). The restrictive strategy also significantly reduced the rate of further bleeding (10% vs. 16%) and systemic adverse events. The physiological mechanism is that aggressive liberal transfusion increases portal and systemic pressures, dislodging early hemostatic clots and precipitating rebleeding.

Transfusion Dosing Principles

• In a non-bleeding, hemodynamically stable adult of average size (~70 kg), one unit of packed red blood cells (PRBCs) increases the circulating hemoglobin by approximately 1.0 g/dL and the hematocrit by approximately 3%.
• The modern standard of care mandates a 'single-unit transfusion strategy': administer one single unit of PRBCs, reassess the patient clinically, and recheck the hemoglobin level prior to ordering additional units. Routine ordering of '2 units of PRBCs' for stable inpatients is obsolete and increases the risk of Transfusion-Associated Circulatory Overload (TACO).

---

Acute Transfusion Reactions: Master Differential & Emergency Management

Acute transfusion reactions occur during or within 24 hours of blood product administration. When an adverse reaction occurs, immediate systematic recognition and differentiation are paramount.

Comprehensive Diagnostic & Management Matrix

Detailed Emergency Protocols for Transfusion Reactions

Immediate Universal Transfusion Reaction Protocol

Whenever a patient exhibits fever, chills, dyspnea, back pain, urticaria, or vital sign instability during a blood transfusion:

1. Stop the transfusion immediately. Disconnect the blood administration tubing completely from the patient's intravenous catheter. Do not flush the tubing containing remaining donor blood into the patient.
2. Aspirate and flush the IV catheter with sterile normal saline to maintain reliable intravenous access.
3. Assess Airway, Breathing, Circulation, and Vital Signs: Immediately check for stridor, wheezing, hypotension, or hypoxemia.
4. Clerical Verification: Check the patient's wristband against the blood product unit label to verify ABO/Rh compatibility and correct patient identification.
5. Laboratory Notification & Return: Return the unused blood unit, attached tubing, and blood administration set to the blood bank. Send post-transfusion recipient blood tubes (EDTA lavender-top and plain red-top) and a newly voided urine specimen to the laboratory for:
   • Repeat ABO and Rh typing and crossmatch;
   • Direct Antiglobulin Test (DAT / Coombs test);
   • Visual inspection of post-transfusion plasma for pink/red discoloration (free hemoglobin from intravascular hemolysis);
   • Complete blood count, serum LDH, indirect bilirubin, haptoglobin, and coagulation studies (PT/INR, aPTT, fibrinogen);
   • Urinalysis for free hemoglobinuria.

TRALI vs. TACO: Critical Board Discrimination

TRALI and TACO represent the two leading causes of transfusion-related mortality. Both present within 6 hours of transfusion with acute hypoxemic respiratory failure and bilateral pulmonary infiltrates. Correctly differentiating between them is a high-yield board competency because their medical therapies are diametrically opposed:

                    TRALI versus TACO COMPARISON

  CLINICAL FEATURE       TRALI                         TACO
  ───────────────────────────────────────────────────────────────────
  Pathophysiology        Non-cardiogenic capillary     Cardiogenic hydrostatic
                         leak (neutrophil-mediated)    volume overload
  Blood Pressure         Hypotension (or normal)       Hypertension (systolic surge)
  Body Temperature       Fever (often >38°C)           Typically afebrile (normal)
  Jugular Veins / CVP    Normal or flat / low CVP      Elevated JVD / high CVP
  Cardiac Auscultation   No gallop, normal S1/S2       S3 gallop present
  BNP / NT-proBNP        Normal or mildly elevated     Markedly elevated (>1.5x)
  Pulmonary Edema Fluid  Exudative (high protein)      Transudative (low protein)
  Fluid Balance          Normal or depleted            Severely positive
  Response to Diuretics  Ineffective; causes severe    Rapid, dramatic improvement
                         hypotensive collapse          in oxygenation and dyspnea
  Core Treatment         Low-tidal mechanical vent,    Upright posture, O2, IV
                         IV fluids for hypotension     Furosemide 20-40 mg

• Critical Exam Pearl: Transfusion-Related Acute Lung Injury is treated like Acute Respiratory Distress Syndrome (ARDS) with lung-protective ventilation and judicious fluid resuscitation if hypotensive. Administering loop diuretics to a patient with TRALI depletes intravascular volume, precipitating profound circulatory shock. In contrast, Transfusion-Associated Circulatory Overload requires aggressive diuresis with IV furosemide.

---

Life-Threatening Coagulopathic Emergencies

Thrombotic Thrombocytopenic Purpura (TTP)

Thrombotic Thrombocytopenic Purpura is a fulminant, life-threatening hematologic emergency with a historical mortality exceeding 90% if untreated, which decreases to <15% with prompt recognition and emergency Therapeutic Plasma Exchange (TPE).

                      TTP PATHOPHYSIOLOGY CASCADE

       Autoantibodies (IgG) against ADAMTS13 Metalloprotease
                                 │
                                 ▼
          Severe ADAMTS13 Enzyme Deficiency (<10% Activity)
                                 │
                                 ▼
       Failure to Cleave Ultra-Large von Willebrand Factor Multimers
                                 │
                                 ▼
       Spontaneous Platelet Adhesion & Microvascular Thrombosis
                                 │
       ┌─────────────────────────┴─────────────────────────┐
       ▼                                                   ▼
Microvascular Occlusion & Ischemia           Severe Platelet Consumption
(Brain, Kidney, Heart)                       (Thrombocytopenia <30,000/uL)
       │                                                   │
       ▼                                                   ▼
RBC Shearing (MAHA / Schistocytes)           Mucocutaneous Bleeding (Purpura)

Pathophysiology & Molecular Mechanism

• Under physiological conditions, endothelial cells synthesize and release ultra-large von Willebrand factor (ULvWF) multimers. The plasma zinc metalloprotease ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) specifically cleaves these reactive multimers into smaller, less adhesive fragments.
• In acquired (autoimmune) TTP, circulating IgG autoantibodies neutralize or clear ADAMTS13, resulting in severe enzyme deficiency (<10% normal activity).
• Uncleaved ULvWF multimers bind avidly to platelet glycoprotein Ib/IX receptors, initiating spontaneous, widespread platelet aggregation and the formation of rich microvascular platelet-vWF thrombi throughout the microcirculation.
• These microthrombi produce mechanical shearing of passing erythrocytes—generating fragmented red cells (schistocytes or 'helmet cells') and intravascular hemolysis—while simultaneously causing end-organ tissue ischemia.

Clinical Presentation: The Diagnostic Pentad

The classic pentad of TTP includes:

1. Microangiopathic Hemolytic Anemia (MAHA): Intravascular hemolysis with abundant schistocytes on peripheral blood smear (typically >1-2% of RBCs), marked indirect hyperbilirubinemia, elevated serum LDH (>1000 U/L), and low/undetectable serum haptoglobin with a negative direct antiglobulin (Coombs) test.
2. Severe Thrombocytopenia: Marked reduction in circulating platelets, typically <20,000 to 30,000/µL, resulting in petechiae, purpura, ecchymoses, epistaxis, or gingival bleeding.
3. Fluctuating Neurologic Symptoms: Present in over 60% of cases; characteristically waxing and waning due to transient cerebral microthrombosis. Manifestations range from mild headache, confusion, and expressive aphasia to focal motor deficits, seizures, and coma.
4. Renal Dysfunction: Usually mild to moderate (elevated serum creatinine, microscopic hematuria, mild proteinuria); acute anuric renal failure is uncommon in TTP (which distinguishes it from Hemolytic Uremic Syndrome).
5. Fever: Present in approximately 20-30% of cases, typically low-grade.

Critical Clinical Caveat: The complete pentad is present in fewer than 5% to 10% of patients at initial presentation. Modern diagnostic criteria mandate that the presence of unexplained MAHA and thrombocytopenia alone (the dyad), in the absence of an alternative diagnosis (such as DIC or severe sepsis), is sufficient to establish a presumptive diagnosis and trigger emergency therapy.

Diagnostic Confirmation

• ADAMTS13 Activity Level: Diagnostic confirmation requires demonstrating ADAMTS13 activity <10% (normal: 67-150%). An ADAMTS13 inhibitor (autoantibody) assay should be obtained concurrently.
• Management Mandate: Blood samples for ADAMTS13 testing must be drawn prior to initiating plasma exchange, but treatment must NEVER be delayed while awaiting the ADAMTS13 test result (which often requires several days to return from reference laboratories).
• Coagulation Studies: Routine coagulation parameters—PT/INR, aPTT, and fibrinogen—are characteristically NORMAL in isolated TTP. This is a pivotal board differentiator from Disseminated Intravascular Coagulation (DIC), where coagulation factors are consumed and PT/aPTT are prolonged.

Emergency Therapeutic Management

1. Therapeutic Plasma Exchange (TPE / Plasmapheresis):
   • The absolute cornerstone of therapy. TPE must be initiated on an emergent basis (within 4 to 8 hours of clinical suspicion).
   • Mechanisms: Removes circulating IgG anti-ADAMTS13 autoantibodies, removes ultra-large vWF multimers, and infuses functional ADAMTS13 enzyme present in donor plasma.
   • Regimen: 1.0 to 1.5 plasma volume exchange daily using fresh frozen plasma or solvent-detergent treated plasma until platelet count recovers to >150,000/µL and LDH normalizes for at least two consecutive days.
   • Bridging: If TPE is delayed due to vascular access placement or transfer logistics, infuse Fresh Frozen Plasma (15-30 mL/kg IV) to provide exogenous ADAMTS13 until TPE can begin.
2. Systemic Corticosteroids:
   • High-dose corticosteroids suppress anti-ADAMTS13 autoantibody production: Methylprednisolone 1,000 mg IV daily for 3 days, followed by oral Prednisone 1 mg/kg/day with a gradual taper.
3. Caplacizumab (Anti-vWF Nanobody):
   • A bivalent humanized variable-domain immunoglobulin fragment that specifically targets the A1 domain of vWF, blocking its interaction with platelet glycoprotein Ib receptors. Administered as an initial 10 mg IV bolus prior to first TPE, followed by 10 mg subcutaneous daily. Accelerates platelet recovery and dramatically reduces thromboembolic complications and refractory disease.
4. Rituximab (Anti-CD20 Monoclonal Antibody):
   • Administered (375 mg/m² IV weekly x 4 doses) in acute autoimmune TTP to eradicate B-cell clones producing anti-ADAMTS13 antibodies, reducing relapse rates.

The Critical Platelet Transfusion Contraindication

• PLATELET TRANSFUSIONS ARE STRICTLY CONTRAINDICATED IN TTP.
• Transfusing exogenous platelets into a patient with active TTP provides immediate substrate for ultra-large vWF multimers, exacerbating microvascular thrombosis. This phenomenon—colloquially termed 'adding fuel to the fire'—has precipitated acute stroke, acute myocardial infarction, cardiovascular collapse, and immediate death.
• Platelet transfusion is reserved solely for patients with catastrophic, immediately life-threatening active hemorrhage (e.g., symptomatic intracranial hemorrhage).

---

Disseminated Intravascular Coagulation (DIC)

Disseminated Intravascular Coagulation is a secondary clinicopathologic syndrome characterized by the systemic, uncontrolled activation of coagulation, resulting in diffuse microvascular fibrin deposition (thrombosis) and the simultaneous consumption of platelets and clotting factors (consumptive coagulopathy and severe bleeding).

                      DIC PATHOPHYSIOLOGIC PARADOX

            Systemic Trigger (Sepsis, Trauma, Malignancy, Obstetric)
                                 │
                                 ▼
            Massive Tissue Factor (TF) Exposure & Release
                                 │
                                 ▼
                Uncontrolled Thrombin Generation
                                 │
       ┌─────────────────────────┴─────────────────────────┐
       ▼                                                   ▼
DIFFUSE MICROVASCULAR THROMBOSIS              CONSUMPTIVE COAGULOPATHY
• Fibrin deposition in arterioles             • Severe Platelet Depletion
• Microvascular shear (Schistocytes)          • Clotting Factor Consumption
• Multi-Organ Dysfunction Syndrome             (I, II, V, VIII, X depleted)
  (AKI, Liver, ARDS, Encephalopathy)          • Secondary Hyperfibrinolysis
                                                           │
                                                           ▼
                                              UNCONTROLLED PROFUSE BLEEDING
                                              (IV sites, incisions, mucosa)

Pathophysiology & Etiologic Triggers

DIC is never a primary disease; it is always provoked by an underlying condition that introduces procoagulant materials into the circulation:

• Sepsis and Severe Infection (46%): Bacterial endotoxins (lipopolysaccharide from Gram-negative bacilli) and inflammatory cytokines (IL-1, IL-6, TNF-alpha) cause massive endothelial expression of Tissue Factor (TF) and downregulate natural anticoagulant pathways (Protein C, Protein S, Antithrombin III).
• Severe Trauma & Burns: Extensive crush injury, neurotrauma (release of brain thromboplastin), and hypothermia/acidosis.
• Obstetric Catastrophes: Placental abruption, amniotic fluid embolism (rich in tissue factor), retained dead fetus syndrome, and preeclampsia/HELLP syndrome.
• Malignancy: Acute Promyelocytic Leukemia (APL / AML M3, where malignant promyelocytes express high levels of tissue factor and annexin II, producing hyperfibrinolytic DIC) and metastatic adenocarcinomas (pancreas, prostate, lung).

Laboratory Diagnostic Profile

The hallmark of DIC is the simultaneous depletion of clotting factors and excessive fibrin turnover:

1. Prolonged Prothrombin Time (PT/INR) and activated Partial Thromboplastin Time (aPTT): Caused by consumptive exhaustion of plasma coagulation factors (Fibrinogen, Prothrombin, Factors V, VIII, and X).
2. Severe Thrombocytopenia: Typically <50,000 to 100,000/µL due to continuous platelet incorporation into widespread microvascular thrombi.
3. Marked Hypofibrinogenemia: Plasma fibrinogen levels fall severely (<100 mg/dL). Fibrinogen is an acute-phase reactant; a 'low-normal' fibrinogen in a septic, critically ill patient reflects active consumptive depletion.
4. Markedly Elevated Fibrin Degradation Products (FDPs) and D-Dimer: Excessive secondary plasmin generation breaks down crosslinked fibrin mesh, generating D-dimer levels often >10-20 times the upper limit of normal.
5. Peripheral Blood Smear: Demonstrates moderate schistocytes (fragmented RBCs) in approximately 50% of cases, reflecting mechanical erythrocyte disruption across intravascular fibrin mesh.

Differential Diagnosis of Microangiopathic & Consumptive Thrombocytopenias

Emergency Supportive Hemostatic Management

1. Treat the Underlying Cause: DIC cannot be arrested without eliminating the primary trigger: broad-spectrum antibiotics and surgical source control for sepsis, immediate evacuation/delivery of the uterus for placental abruption, stabilization of trauma, or all-trans retinoic acid (ATRA) for acute promyelocytic leukemia.
2. Blood Product Replacement Protocol (Indicated for Active Hemorrhage or Invasive Procedures):
   • Cryoprecipitate: The single most effective product to replete fibrinogen. Administer 10 units (1 to 2 pools) of cryoprecipitate to maintain plasma fibrinogen >100 to 150 mg/dL (target >150-200 mg/dL in severe obstetric hemorrhage).
   • Platelet Transfusion: Transfuse pooled or apheresis platelets to maintain a platelet count >50,000/µL in the presence of active bleeding or prior to urgent surgical procedures (maintain >20,000/µL in non-bleeding patients at high risk of hemorrhage).
   • Fresh Frozen Plasma (FFP): Indicated for active bleeding in the setting of prolonged PT/INR (>1.5) or prolonged aPTT. Standard dosing is 15 to 30 mL/kg IV (typically 3 to 4 units in an adult).
   • Packed Red Blood Cells (PRBCs): Administer to restore oxygen-carrying capacity, maintaining hemoglobin >7.0 to 8.0 g/dL.
   • Role of Anticoagulation (Heparin): Routine heparin is contraindicated in acute bleeding DIC. Low-dose intravenous unfractionated heparin (5-10 units/kg/h) is considered only in predominant prothrombotic phenotypes without active hemorrhage, such as purpura fulminans, retained dead fetus syndrome, or extensive acral ischemic gangrene.